title: Possible novel agents in marginal zone lymphoma.
abstract: Efficacy, safety and mechanisms of action of novel agents in marginal zone lymphoma patients, both with a nodal and extranodal presentation, are reviewed. Data on lenalidomide, bortezomib and90yttrium-ibrutumomab tiuxetan are obtained from trials specifically designed for patients affected by marginal zone lymphoma and with various disease presentations. The role of targeted agents, such as obinutuzumab, ibrutinib and idelalisib, and of some very new drugs (venetoclax, copanlisib, ublituximab and TGR-1202) is also discussed, taking into account the most relevant experiences in patients with indolent non-Hodgkin's lymphomas. A glance to some possible drug combinations will also be provided, along with an update of the most relevant ongoing trials.
authors.affiliation: Institute of Haematology "L. e A. Seràgnoli", Via Massarenti, 9, 40138 Bologna, Italy. Electronic address: pierluigi.zinzani@unibo.it.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: Institute of Haematology "L. e A. Seràgnoli", Via Massarenti, 9, 40138 Bologna, Italy. Electronic address: alessandro.broccoli@studio.unibo.it.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Broccoli
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D000077269:Lenalidomide; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D010880:Piperidines; D011687:Purines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019086:Bridged Bicyclo Compounds, Heterocyclic; D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D011799:Quinazolines; D052999:Quinazolinones; D013449:Sulfonamides; C551803:ibrutinib; C422802:ibritumomab tiuxetan; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide; D000225:Adenine; C579720:venetoclax; C543332:obinutuzumab; C000619007:ublituximab; C000589253:copanlisib; C552946:idelalisib
keywords: BTK; Bortezomib; Clinical trial; Copanlisib; Ibritumomab tiuxetan; Ibrutinib; Idelalisib; Lenalidomide; Marginal zone lymphoma; Obinutuzumab; PI3K; Radioimmunotherapy; Rituximab; TGR-1202; Ublituximab; Venetoclax